Post-Marketing Study for Evaluation of Gadoterate Meglumine Immediate Adverse Reactions within One Hour in Children Younger than Two Years Old

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022694

Enrollment

Unknown

Registered

2019-04-22

Start date

2018-09-24

Completion date

Unknown

Last updated

2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Adverse Reaction

Interventions

Case Series:Gd-DOTA

Eligibility

Sex/Gender

All

Age

No minimum to 2 Years

Inclusion criteria

Inclusion criteria: Planing to use Gd-DOTA CE-MRI at younger than 2 Years old children.

Exclusion criteria

Exclusion criteria: No

Design outcomes

Primary

Measure	Time frame
Acute Adverse Reation;	—

Countries

China

Contacts

Public ContactLi Xin

Tianjin Children‘s Hospital

xinli.tj@163.com+86 13821536736

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026